GSK lifts emerging market bet with full control of Indonesia arm

Tags: News
GlaxoSmithKline is betting more on Indonesia by taking full control of its consumer healthcare unit in the country, underscoring a drive by the drugmaker to build up its presence in fast-growing emerging markets.

The move, announced on Friday, mirrors the British company's strategy in India, where it recently increased its stake in local units.

GSK has paid 465 billion rupiahs to Sarasvati Venture Capital for the 30 percent of the Indonesian consumer healthcare operation it did not previously own, giving it 100 percent of a business that sells non-prescription products like Panadol painkillers and Sensodyne toothpaste.

At the same time, GSK has sold its non-core local Insto eye drops brand to Pharma Healthcare and agreed to divest its factory at Bogor, Indonesia, to PT Pharma Healthcare for a combined total of 133 billion rupiahs.

"This transaction is a further example of GSK focusing its business in strategically important growth markets such as Indonesia. It will also simplify operations in the Indonesian business," David Redfern, GSK's chief strategy officer, said.

GSK's Indonesian consumer healthcare business has seen significant growth over the last five years, with net sales reaching close to 50 million pounds in 2013, up from around 16 million in 2008.

The company is committed to emerging markets as a key growth platform - based on rising demand for healthcare among growing middle class populations - despite recent problems in China, where sales have been hit by bribery allegations.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Tighter disclosure norms will help public shareholders

    The Securities and Exchange Board of India (Sebi) has proposed changes in listing agreements between companies and stock exchanges, laying down manage

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Nigavekar

Why UGC must focus on quality

In a vast country like India, where there are pressures ...

Rajgopal Nidamboor

The sum total of our conscious experience

All of us epitomise a multiplicity of conscious thoughts. This ...

Gautam Gupta

Don’t let success kill the essence of the concept

In 1999 when my mother started her own label, we ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture